Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Previously Treated
100%
Phase I Study
100%
Small Cell Lung Cancer
100%
RAD001
100%
Everolimus
100%
Sensitive Relapse
60%
Disease Control Rate
40%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
40%
Mammalian Target of Rapamycin (mTOR)
20%
S6 Kinase 1 (S6K1)
20%
Disease Progression
20%
Neutropenia
20%
Overall Survival
20%
Protein Expression
20%
Median Survival
20%
Diarrhea
20%
First Cycle
20%
Partial Response
20%
Thrombocytopenia
20%
Pneumonitis
20%
Tumor Tissue
20%
Antitumor Activity
20%
Median Time
20%
Best Response
20%
Acute Renal Failure
20%
Time to Progression
20%
Stable Disease
20%
Disease Control
20%
Elevated Transaminases
20%
MTOR Inhibitor
20%
Previously Treated Patients
20%
Phosphorylated Akt
20%
Combination Regimen
20%
Promising Target
20%
Well Tolerated
20%
Kinase Protein
20%
Medicine and Dentistry
Small Cell Lung Cancer
100%
Everolimus
100%
Diseases
66%
Biological Marker
16%
Neoplasm
16%
Infection
16%
Overall Survival
16%
Diarrhea
16%
Protein Expression
16%
Signal Transduction
16%
Antineoplastic Activity
16%
Protein Kinase B
16%
Akt Signaling
16%
Neutropenia
16%
Disease Exacerbation
16%
Thrombocytopenia
16%
Mechanistic Target of Rapamycin
16%
Elevated Transaminases
16%
Acute Kidney Injury
16%
Mammalian Target of Rapamycin Inhibitor
16%
S6 Kinase
16%
Pharmacology, Toxicology and Pharmaceutical Science
Small Cell Lung Cancer
100%
Everolimus
100%
Diseases
66%
Protein Kinase B
33%
Biological Marker
16%
Neoplasm
16%
S6 Kinase
16%
Mammalian Target of Rapamycin
16%
Disease Exacerbation
16%
Infection
16%
Overall Survival
16%
Neutropenia
16%
Thrombocytopenia
16%
Antitumor Activity
16%
Acute Kidney Failure
16%
Diarrhea
16%
Hypertransaminasemia
16%
Mammalian Target of Rapamycin Inhibitor
16%
Immunology and Microbiology
Everolimus
100%
Lung
100%
Sirolimus
33%
Signal Transduction
16%
Infectious Disease
16%
Overall Survival
16%
Pneumonitis
16%
Antineoplastic Activity
16%
Protein Expression
16%
Akt Signaling
16%
Infection
16%
Phosphotransferase
16%
Kinase
16%